Follow us on:

EDX Medical Group targets NHS pneumonia cases with breakthrough rapid test partnership (Video)

EDX Medical Group Plc (AQSE:EDX) has teamed up with Cambridge University Hospitals NHS Foundation Trust and the UK Health Security Agency to create a rapid hospital-acquired pneumonia test set to transform diagnosis and treatment across the NHS. Sir Chris Evans reveals how this high-profile collaboration could save thousands of lives, free up vital hospital beds, and open the door to a new era of precision medicine.

EDX Medical Group Plc develops advanced digital diagnostic products and services that enable personalised treatments for cancer, heart disease, and infectious diseases.

Share on:

You might also enjoy reading EDX Medical Group to complete the development of new pneumonia test

Find more news, interviews, share price & company profile here for:EDX Medical Group Plc

Search

Other Interviews

EDX Medical plc Game-Changing Blood Test Targets Early Detection of Testicular Cancer (Video) April 14, 2025
EDX Medical Group’s Prostate Cancer ‘Super Test’ Aims to Revolutionise Early Detection (Video) February 18, 2025
EDX Medical Group: Innovating Digital Diagnostics and Cancer Testing (VIDEO) June 24, 2024

More News

EDX Medical Group targets NHS pneumonia cases with breakthrough rapid test partnership (Video) August 11, 2025
EDX Medical Group to complete the development of new pneumonia test August 8, 2025
EDX Medical and Spire Healthcare sign MOU for diagnostic partnership June 16, 2025
Professor Sir Chris Evans on EDX Medical’s new testicular cancer test (AQSE:EDX) April 25, 2025
EDX launches groundbreaking blood test for testicular cancer April 23, 2025
Breakthrough blood test set to transform testicular cancer detection April 16, 2025
EDX Medical plc Game-Changing Blood Test Targets Early Detection of Testicular Cancer (Video) April 14, 2025
EDX Medical Group to launch highly accurate early detection test for testicular cancer April 11, 2025
A powerful push for prostate cancer awareness April 10, 2025
EDX Medical Group raises £3.0 million to accelerate its prostate cancer ‘super test’ March 20, 2025

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2025 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.